Two Heart Drugs Fell Flat Against Placebo. Was the Theory Wrong?

For years, cardiologists treated two experimental drugs from Novartis and Novo Nordisk as a likely next step in preventing heart attacks and strokes. On Saturday, full trial data made that hope much harder to hold.

According to The New York Times, the drugs were no better than placebos by every measure. That is not a narrow miss or a mixed result. It is a clean null finding, and in cardiovascular medicine those results often teach more than successes do.

A verdict without ambiguity

Drug trials often end with partial wins: a benefit in one subgroup, a secondary endpoint worth exploring, an encouraging trend that falls short of statistical significance. Those outcomes give companies a reason to keep going. This time there was little of that to work with.

Both companies built their programs on the belief that their targets would lower cardiovascular risk. Patients enrolled in large, expensive trials expecting to help test that belief. The data delivered a plain answer.

Study design or flawed science?

The central question, as the Times framed it, is whether the trials failed because of how they were designed or because the underlying hypotheses about heart disease were wrong. The two explanations lead in very different directions.

If design is to blame, the problems could include:

• enrolling the wrong patients,
• following them for too short a time, or
• choosing endpoints too blunt to detect a real effect.

Under that reading, the science may still be sound and simply in need of a better test.

The second possibility is harder to accept. Some biological pathways that look clearly linked to heart disease in observational studies and genetic analyses may not change outcomes when a drug acts on them. A risk factor can travel alongside disease without driving it. Cardiology has been here before: several promising treatments that improved lab markers did nothing to reduce heart attacks or deaths.

The stakes for industry and patients

For Novartis and Novo Nordisk, the results reach beyond the two drugs. Large pharmaceutical companies have bet heavily on cardiometabolic medicine. Novo Nordisk in particular built much of its recent growth on drugs for obesity and metabolic disease. A double failure tells investors that ambitious bets in this field can still collapse completely.

For patients, the effect is quieter but real. People with persistent cardiovascular risk, including many already on standard therapy, were waiting for these drugs. They now have fewer new options in sight, and researchers face the slow work of regrouping.

What comes next

Researchers will go through the full datasets looking for anything that could separate a failed test from a failed theory. Subgroup analyses, biomarker data and long-term follow-up may offer clues. Some scientists will argue for a second, better-designed trial. Others will say the evidence is strong enough to move on.

Either way, Saturday's results are a useful correction. Heart disease remains the world's leading killer partly because its biology is more complicated than any single target suggests. Negative trials like these remove ideas that do not hold up, and they show researchers where to look next.